|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This preliminary study identifies MBL and ficolin-2 as potential biomarkers for the development of HCC in chronic HCV infection.
|
30798068 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mannose-binding lectin 2 (MBL2) was further identified as a direct target of miR-942-3p and possessed a negative correlation with miR-942-3p expression and unfavorable survival in patients with HCC.
|
31046434 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these data reveal that MBL may impact on tumor development by shaping the tumor microenvironment <i>via</i> its interaction with the local stromal cells, and also suggests its potential therapeutic use for the treatment of HCC.
|
30713782 |
2019 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We observed that the human hepatoma cell line HuH7.5, which is routinely used for the study of hepatotropic viruses, is deficient in expression of MBL, ficolin-2 and ficolin-3.
|
30747617 |
2019 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Collectively, this meta-analysis proved that VDR rs7975232, VDR rs2228570, VEGF rs699947, VEGF rs3025039, IL-18 rs1946518, and MBL rs7096206 polymorphisms may confer susceptibility to HCC in certain populations.
|
31830994 |
2019 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MBL2 rs11003123 polymorphism may be a marker for the risk of HCC occurrence in patients with HBV-related cirrhosis in the Chinese population.
|
27298104 |
2016 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, both IL-1β and IL-6 were inversely associated with plasma MBL2 level.The mutations in MBL2 could lead to compromised innate immunity, and possibly lead to elevated HCC risk, and a novel haplotype HXB has been identified with a rate of 12.5%.
|
27557564 |
2016 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that the MBL2 polymorphism rs7096206 is associated with HCC susceptibility and has the potential to serve as a biomarker to detect populations at increased HCC risk.
|
25787238 |
2015 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, interactome analysis of these proteins with midkine (MDK), dickkopf-1 (DKK-1), current standard HCC biomarker alpha-fetoprotein (AFP), its interacting partners in conjunction with HCC-specific circulating and liver deregulated miRNAs target filtration highlighted seven novel statistically significant putative biomarkers including complement component 8, alpha (C8A), mannose binding lectin (MBL2), antithrombin III (SERPINC1), 11β-hydroxysteroid dehydrogenase type 1 (HSD11B1), alcohol dehydrogenase 6 (ADH6), beta-ureidopropionase (UPB1) and cytochrome P450, family 2, subfamily A, polypeptide 6 (CYP2A6).
|
26414287 |
2015 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, it was found that there was an association between the mbl2 AO/OO genotype and severe hepatitis B (SHB) or liver cirrhosis (LC) (LC vs. HC:OR=3.66, 95%CI, 2.38-5.63; SHB vs. HC, OR=3.88, 95%CI, 2.26-6.64), but there was no relationship between the mbl2 AO/OO genotype and hepatocellular carcinoma (HCC) (OR=1.26, 95%CI, 0.82-1.94).
|
24116040 |
2013 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MBL-2 genotypes were corelated with the growth patern, tumour size and pretransplant α-fetoprotein (AFP) level of HCC patients.
|
21733090 |
2011 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data do not seem to suggest a role for MBL2 and MASP2 polymorphisms in HCC susceptibility either for HBV-HCV infection-dependent HCC or for HCC raised as a consequence of exposure to different risk factors.
|
18221301 |
2008 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
However, the low MBL genotypes had a dose-dependent correlation with the cirrhosis and hepatocellular carcinoma in progressed carriers with odds ratios of 1.36 and 3.21 for the low and extremely low MBL genotypes, respectively (P = .01).
|
16231358 |
2005 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, the low MBL genotypes had a dose-dependent correlation with the cirrhosis and hepatocellular carcinoma in progressed carriers with odds ratios of 1.36 and 3.21 for the low and extremely low MBL genotypes, respectively (P = .01).
|
16231358 |
2005 |